Роль цитокинов в патогенезе злокачественных новообразований

213.Kim R. Cancer immunoediting from immune surveillance to immune escape / R. Kim, M. Emi, K. Tanabe // Immunology. – 2007. – Vol. 121. – N 1. – P. 1–14.

214.Kim R. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses / R. Kim, M. Emi,

K.Tanabe // Cancer Biol. Ther.–  2005. – Vol. 4. – N 9. – P. 924–933.

215.Kim R. Tumor-driven evolution of immunosuppressive networks during malignant progression / R. Kim, M. Emi, K. Tanabe,

K.Arihiro // Cancer Res. – 2006. – Vol. 66. – N 11. – P. 5527–5536.

216.Kim S. H. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18 / S. H. Kim,

M.Eisenstein, L. Reznikov et al. // Proc. Natl. Acad. Sci. USA. – 2000. – Vol. 97. – P. 1190–1195.

217.Kioi M. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy / M. Kioi, S. Takahashi, M. Kawakami et al. // Cancer Res. – 2005. – Vol. 65. – N 18. – P. 8388–8396.

218.Konishi N. Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma / N. Konishi,

C.Miki, T. Yoshida et al. // Oncology.–  2005. – Vol. 68. – P. 138–145.

219.Konsti J. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer / J. Konsti, M. Lundin, H. Joensuu et al. // BMC Clin. Pathol. – 2011. – Vol. 11. – P. 3.

220.Kirkegaard H. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study / H. Kirkegaard, N. F. Johnsen, J. Christensen, K. Frederiksen // BMJ. – 2010. – Vol. 341. – P. c5504.

221.Kroeger K. M. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88– and p38 alpha-dependent pathway / K.M . Kroeger, B. M. Sullivan, R. M. Locksley // J. Leukoc. Biol.–  2009. – Vol. 86. – N 4. – P. 769–778.

222.Kulbe H. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells / H. Kulbe, R. Thompson, J. L. Wilson et al. // Cancer Res. – 2007. – Vol. 67. – N 2. – P. 585–592.

223.Kumar S. Mechanics, malignancy, and metastasis: the force journey of a tumor cell / S. Kumar, V. M. Weaver // Cancer Metastasis Rev. – 2009. – Vol. 28. – N 1–2. – P. 113–127.

224.Kuwano K. Signal transduction pathways of apoptosis and inflammation induced by the tumor necrosis factor receptor family / K. Ku- wano,N.Hara//Am. J.Respir.CellMol.Biol. –2000. –Vol.22. –N2. –

P.147–149.

225.KyewskiB.Acentralroleforcentraltolerance/B.Kyewski,L.Klein// Annu Rev. Immunol. – 2006. – Vol. 24. – P. 571–606.

226.La E. Role of intracellular interleukin-1 receptor antagonist in skin carcinogenesis / E. La, J. E. Rundhaug, S. M. Fischer // Mol. Carcinog. – 2001. – Vol. 30. – N 4. – P. 218–223.

61

227.Lahm H. Selective suppression of cytokine secretion in whole blood cell cultures of patients with colorectal cancer / H. Lahm,

M.Schindel, L. Frikart et al. // Br. J. Cancer. – 1998. – Vol. 78. – N 8. – P. 1018–1023.

228.Lamagna C. Dual role of macrophages in tumor growth and angiogenesis / C. Lamagna, M. Aurrand-Lions, B. A. Imhof //

J.Leukoc. Biol. – 2006. – Vol. 80. – N 4. – P. 705–713.

229.Laurence C. M. B cells amplify IFN- γ production by T cells via a TNF-α-mediated mechanism / C. M. Laurence, A. M. Laurie et al. // The Journal of Immunology. – 2007. – Vol. – 179. – P. 4857–4866

230.Le N. H. Tumour-stroma interactions in colorectal cancer: converging onbeta-cateninactivationandcancerstemness/N. H.Le,P.Franken,

R.Fodde // Br. J. Cancer. – 2008. – Vol. 98. – N 12. – P. 1886–1893.

231.Leach S. T. Local and systemic interleukin-18 and interleukin-18–bind- ing protein in children with inflammatory bowel disease / S.T . Leach,

I.Messina, D. A. Lemberg et al. // Inflamm. Bowel Dis.–  2008. – Vol. 14. – N 1. – P. 68–74.

232.Lee I. Y. Interleukin-4 inhibits the vascular endothelial growth factorand basic fibroblast growth factor-induced angiogenesis in vitro / I. Y. Lee, J. Kim, E. M. Ko et al. // Mol. Cells. – 2002. – Vol. 14. – P. 115–121.

233.Lehner T. Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation / T. Lehner // Immunology. – 2008. – Vol. 123. – N 1. – P. 40–44.

234.Lejeune F. J. Efficiency of recombinant human TNF in human cancer therapy / F. J. Lejeune, D. Lienard, M. Matter, C. Ruegg // Cancer Immun. – 2006. – Vol. 6. – P. 6.

235.de Lemos, Rieper C. Characterization and potential clinical applicationsofautoantibodiesagainstcytokines/RieperC.deLemos,

P.Galle, M. B. Hansen // Cytokine Growth Factor Rev. – 2009. – Vol. 20. – N 1. – P. 61–75.

236.Lesina M. Stat3 / Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer / M. Lesina, M. U. Kurkowski, K. Ludes et al. // Cancer Cell. – 2011. – Vol. 19. – N 4. – P. 456–469.

237.Letourneau S. IL-2 / anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2Receptor α subunit CD25 / S. Letourneau, M. M. Ester van Leeuwen, Carsten Krieg et al. // Proc. Natl. Acad. Sci. U S A. – 2010. – Vol. 107. – N 5. –

P.2171–2176.

238.Levi-Montalcini R. A diffusible agent of mouse sarcoma producing hyperplasia of sympathetic ganglia and hyper neurotization of viscera in the chick embryo / R. Levi-Montalcini, V. Hamburger //

J.Exp. Zool. – 1953. – Vol. 123. – P. 233–288.

239.Lewis A. M. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in

62

cancer treatment / A. M. Lewis, S. Varghese, H. Xu, H. R. Alexander // J. Transl. Med. – 2006. – Vol. 4. – P. 48.

240. LiA.IL-8directlyenhancedendothelialcellsurvival,proliferation,and matrix metalloproteinases production and regulated angiogenesis / A. Li, S. Dubey, M. L. Varney et al. // J. Immunol. – 2003. – Vol. 170. – P. 3369–3376.

241. Li B. Special regulatory T-cell review: FOXP3 biochemistry in regulatory T cells – how diverse signals regulate suppression / B. Li, M. I. Greene // Immunology. – 2008. – Vol. 123. – N 1. – P. 17–19.

242. LiG.Achaperoneprotein-enrichedtumorcelllysatevaccinegenerates protective humoral immunity in a mouse breast cancer model / G. Li, S. Andreansky, G. Helguera et al. // Mol. Cancer Ther. – 2008. – Vol. 7. – N 3. – P. 721–729.

243. Li X. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone / X. Li, R. Loberg, J. Liao et al. // Cancer Res. – 2009. – Vol. 69. – P. 1685–1692.

244. Li Z. Paradoxical roles of IL-4 in tumor immunity / Z. Li, L. Chen, Z. Qin // Cell Mol. Immunol. – 2009. – Vol. 6. – N 6. – P. 415–422.

245. Lima L. G. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner / L. G. Lima, R. Chammas, R. Q. Monteiro et al. // Cancer Lett. – 2009. – Vol. 283. – N 2. – P. 168–175.

246. Lin M. T. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of antiapoptotic gene mcl-1 / M. T. Lin, C. Y. Juan, K. J. Chang et al. // Carcinogenesis. – 2001. – Vol. 22. – N 12. – P. 1947–1953.

247. Lindemann S. Activated platelets mediate inflammatory signaling by regulated interleukin 1 beta synthesis / S. Lindemann, N. D. Tolley, D. A. Dixon et al. // J. Cell Biol. – 2001. – Vol. 154. – P. 485–490.

248. LingK. L.IncreasedfrequencyofregulatoryTcellsinperipheralblood and tumour infiltrating lymphocytes in colorectal cancer patients / K. L. Ling, S. E. Pratap, G. J. Bates et al. // Cancer Immun. – 2007. – Vol. 7. – P. 7.

249. Liu J. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma / J. Liu, Y. Duan, X. Cheng et al. // Biochem. Biophys. Res. Commun. – 2011. – Vol. 407. – N 2. – P. 348–354.

250. Liu Y. Expression cloning and characterization of a human IL-10 receptor / Y. Liu, S. H. Wei, A. S. Ho et al. // J. Immunol. – 1994. – Vol. 152. – P. 1821–1829.

251. Loberg R. D. CCL2 is a potent regulator of prostate cancer cell migration and proliferation / R. D. Loberg, L. L. Day, J. Harwood et al. // Neoplasia. – 2006. – Vol. 8. – P. 578–586.

252. Loddenkemper C. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer / C. Loddenkemper, M. Schernus, M. Noutsias et al. // J. Transl. Med. – 2006. – Vol. 4. – P. 52.

63

253.Lotfi R. Immunotherapy for cancer: promoting innate immunity /

R.Lotfi, H. Schrezenmeier, M. T. Lotze // Front. Biosci.–  2009. – Vol. 14. –

P.818–832.

254.Lu B. T-cell death and cancer immune tolerance / B. Lu, O. J. Finn // Cell Death Differ. – 2008. – Vol. 15. – N 1. – P. 70–79.

255.Lu Y. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion / Y. Lu, Z. Cai, D. L. Galson et al. // Prostate. – 2006. – Vol. 66. – N 12. –

P.1311–1318.

256.Lukacher A. E. IFN-gamma suspends the killing license of antitumor CTLs / A. E. Lukacher // J. Clin. Invest. – 2002. – Vol. 110. – N 10. – P. 1407–1409.

257.Lukaszewicz M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease / M. Lukaszewicz, B. Mroczko, M. Szmitkowski // Pol. Arch. Med. Wewn.–  2007. – Vol. 117. – N 5–6. – P. 247–251

258.Luo D. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis /

D.Luo, Y. Luo, Y. He et al. // Am. J. Pathol. – 2006. – Vol. 169. – N 5. –

P.1886–1898.

259.Luppi F. Interleukin-8 stimulates cell proliferation in non-small cell lungcancerthroughepidermalgrowthfactorreceptortransactivation/

F.Luppi, A. M. Longo, W. I. de Boer et al. // Lung Cancer. – 2007. – Vol. 56. – P. 25–33.

260.Lust J. A. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component / J. A. Lust, M. Q. Lacy, S. R. Zeldenrust et al. // Mayo. Clin. Proc. – 2009. – Vol. 84. – P. 114–122.

261.Ma J. Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8–mediated invasion of prostate cancer cells through suppressing EGR-1 / NF-kappaB synergy / J. Ma, Z. Ren, Y. Ma et al. // J. Biol. Chem. – 2009. – Vol. 284. – N 50. – P. 34600–34606.

262.Mallat Z. Interleukin-18 / interleukin-18 binding protein signaling modulates ischemia-induced neovascularization in mice hindlimb / Z. Mallat, J. S. Silvestre, S. Le Ricousse-Roussanne et al. // Circ. Res. – 2002. – Vol. 91. – N 5. – P. 441–448.

263.Mantovani A. Tumour-associated macrophages as a prototypic type

IIpolarised phagocyte population: role in tumour progression /

A.Mantovani, P. Allavena, A. Sica // Eur. J. Cancer. – 2004. – Vol. 40. – N 11. – P. 1660–1667.

264.Mantovani A. The yin-yang of tumor-associated neutrophils /

A.Mantovani // Cancer Cell. – 2009. – Vol. 16. – N 3. – P. 173–174.

265.Martins S. F. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies / S. F. Martins, R. M. Reis, A. M. Rodrigues et al. // World J. Clin. Oncol. – 2011. – Vol. 2. – N 6. – P. 272–280.

64

266.Mazodier K. Severe imbalance of IL-18 / IL-18BP in patients with secondary hemophagocytic syndrome / K. Mazodier, V. Marin,

D.Novick et al. // Blood. – 2005. – Vol. 106. – N 10. – P. 3483–3489.

267.Mays L. E. Maintaining immunological tolerance with Foxp3 / L.E . Mays, Y. H. Chen // Cell Res.–  2007. – Vol. 17. – N 11. – P. 904–918.

268.McClintock J. Y. Role of IL-6 in systemic angiogenesis of the lung / J. Y. McClintock, E. M. Wagner // J. Appl. Physiol. – 2005. – Vol. 99. – N 3. – P. 861–866.

269.McDonald P. P. Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in human neutrophils / P. P. McDonald, M. P. Russo, S. Ferrini, M. A. Cassatella // Blood. – 1998. – Vol. 92. – N 12. – P. 4828–4835.

270.McFarlane S. M. Differential activation of nuclear factor-kappaB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly / S. M. McFarlane,

G.Pashmi, M. C. Connell et al. // FEBS Lett. – 2002. – Vol. 515. – N 1–3. – P. 119–126.

271.McKenna R. M. Antibodies to interferon-alpha in treated cancer patients: incidence and significance / R. M. McKenna, K. E. Oberg //

J.Interferon Cytokine Res. – 1997. – Vol. 17. – N 3. – P. 141–143.

272.McMahan R. H. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines / R.H . McMahan, J. A. McWilliams, K. R. Jordan et al. // J. Clin. Invest.–  2006. – Vol. 116. – N 9. – P. 2543–2551.

273.Meager A. Anti-cytokine autoantibodies in autoimmunity: preponderanceofneutralizingautoantibodiesagainstinterferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and / or myasthenia gravis / A. Meager, M. Wadhwa, P. Dilger et al. // Clin. Exp. Immunol. – 2003. – Vol. 132. – N 1. – P. 128–136.

274.van der Meide P. H. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action / P. H. van der Meide,

H.Schellekens // Biotherapy. – 1997. – Vol. 10. – N 1. – P. 39–48.

275.Mehrotra P. T. Production of IL-10 by human natural killer cells stimulated with IL-2 and / or IL-12 / P. T. Mehrotra, R. P. Donnelly,

S.Wong et al. // J. Immunol. – 1998. – Vol.160. – N 6. – P. 2637–2644.

276.Menezes H. L. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors / H. L. Menezes, M. J. Jucá, E. G. Gomes et al. // Arq. Gastroenterol. – 2010. – Vol. 47. – N 2. – P. 141–147.

277.Merchant M. S. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing’s sarcoma / M.S . Merchant, X. Yang,

F.Melchionda et al. // Cancer Res.–  2004. – Vol. 64.–  N 22.–  P. 8349–8356.

278.Millar H. J. Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model / H. J. Millar, J. A. Nemeth, F. L. McCabe et al. // Cancer Epidemiol. Biomarkers Prev. – 2008. – Vol. 17. – N 8. – P. 2180–2187.

65

279.Mitsiades C. S. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer / C. S. Mitsiades, V. Poulaki,

N.Mitsiades // J. Endocrinol. – 2003. – Vol. 178. – N 2. – P. 205–216.

280.Miyazaki T. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer /

T.Miyazaki, N. Okada, K. Ishibashi et al. // Jpn.  J. Clin. Oncol. – 2008. – Vol. 38. – P. 839–843.

281.Mocellin S. Interleukin-10 and the immune response against cancer: a counterpoint / S. Mocellin, F. M. Marincola, H. A. Young // J. Leukoc. Biol. – 2005. – Vol. 78. – N 5. – P. 1043–1051.

282.Moll H. P. Neutralizing type I IFN antibodies trigger an IFN-like responseinendothelialcells/H. P.Moll,H.Freudenthaler,A.Zommer et al. // J. Immunol. – 2008. – Vol. 180. – N 8. – P. 5250–5256.

283.Monti P. The CC chemokine MCP-1 / CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity / P. Monti, B. E. Leone, F. Marchesi et al. // Cancer Res. – 2003. – Vol. 63. – N 21. – P. 7451–7461.

284.Mosser D. M. Interleukin-10: new perspectives on an old cytokine / D. M. Mosser, X. Zhang // Immunol. Rev.–  2008. – Vol. 226. – P. 205–218.

285.Murugaiyan G. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis / G. Murugaiyan, A. Mittal, H. L. Weiner // J. Immunol. – 2008. – Vol. 181. – P. 7480–7488.

286.Murugaiyan G. Protumor vs antitumor functions of IL-17 / G. Murugaiyan, B. Saha // J. Immunol.–  2009. – Vol. 183. – N 7. – P. 4169–4175.

287.Mysliwiec P. Combined perioperative plasma endoglin and VEGF-a assessment in colorectal cancer patients / P. Mysliwiec, K. Pawlak,

A.Kuklinski, B. Kedra // Folia. Histochem. Cytobiol. – 2009. – Vol. 47. – N 2. – P. 231–236.

288.Naftali T. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation /

T.Naftali, D. Novick, G. Gabay et al. // Isr. Med. Assoc. J. – 2007. – Vol. 9. – N 7. – P. 504–508.

289.Nagaraj S. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer / S. Nagaraj, K. Gupta, V. Pisarev et al. // Nat. Med. – 2007. – Vol. 13. – N 7. – P. 828–835.

290.Nakao S. Infiltration of COX-2–expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth / S. Nakao, T. Kuwano, C. Tsutsumi-Miyahara et al. // J. Clin. Invest. – 2005. – Vol. 115. – N 11. – P. 2979–2991.

291.Nakazato Y. Interleukin (IL)-1 and IL-4 synergistically stimulate NF-IL6 activity and IL-6 production in human mesangial cells /

Y.Nakazato, T. Hayashida, Y. Kanno et al. // Kidney. Int. – 1998. – Vol. 54. – N 1. – P. 71–79.

292.Nam J. S. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17 /

66

J. S.Nam,M.Terabe,M. J.Kangetal.//CancerRes. –2008. –Vol.68. –

P. 3915–3923.

293. Nelms K. The IL-4Receptor: signaling mechanisms and biologic functions / K. Nelms, A. D. Keegan, J. Zamorano et al. // Annu. Rev. Immunol. – 1999. – Vol. 17. – P. 701–738.

294. Nelson B. H. IL-2, regulatory T cells, and tolerance / B. H. Nelson // J. Immunol. – 2004. – Vol. 172. – N 7. – P. 3983–3988.

295. Neufeld G. Vascular endothelial growth factor (VEGF) and its receptors / G. Neufeld, T. Cohen, S. Gengrinovitch, Z. Poltorak // FASEB J. – 1999. – Vol. 13. – P. 9–22.

296. Neurath M. F. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer / M. F. Neurath, S. Finotto // Cytokine Growth Factor Rev. – 2011. – Vol. 22. – N 2. – P. 83–89.

297. Nikolaus S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation / S. Nikolaus, J. Bauditz, P. Gionchetti et al. // Gut. – 1998. – Vol. 42. – N 4. – P. 470–476.

298. Ning Y. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models / Y. Ning, P. C. Manegold, Y. K. Hong et al. // Int.  J. Cancer. – 2011. – Vol. 128. – N 9. – P. 2038–2049.

299. Novick D. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response / D. Novick, S. H. Kim, G. Fantuzzi et al. // Immunity. – 1999. – Vol. 10. – P. 127–136.

300. Novick D. Interleukin-18 binding protein in the sera of patients with Wegener’s granulomatosis / D. Novick, D. Elbirt, C. A. Dinarello et al. // J. Clin. Immunol. – 2009. – Vol. 29. – N 1. – P. 38–45.

301. O’Boyle G. Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2 / G. O’Boyle, J. G. Brain, J. A. Kirby, S. Ali // Mol. Immunol. – 2007. – Vol. 44. – P. 1944–1953.

302. Ochoa C. E. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis / C. E. Ochoa, S. G. Mirabolfathinejad, V. A. Ruiz et al. // Cancer Prev. Res. – 2011. – Vol. 4. – N 1. – P. 51–64.

303. O’Connor P. M. Mechanisms by which inflammation may increase intestinalcancerriskininflammatoryboweldisease/P. M.O’Connor, T. K. Lapointe, P. L. Beck, A. G. Buret // Inflamm. Bowel Dis. – 2010. – Vol. 16. – N 8. – Р. 1411–1420.

304. Okada H. Gene therapy and biologic therapy with interleukin-4 / H. Okada, N. Kuwashima // Curr. Gene Ther.–  2002. – Vol. 2. – P. 437–450.

305. OlejniczakK.Biologicalpropertiesofinterleukin2anditsroleinpathogenesis of selected diseases – a review / K. Olejniczak, A. Kasprzak // Med. Sci. Monit. – 2008. – Vol. 14. – N 10. – P. RA179– RA189.

306. Oliveira S. H. The role of chemokines and chemokine receptors in eosinophil activation during inflammatory allergic reactions / S. H. Oliveira, N. W. Lukacs // Braz.  J. Med. Biol. Res.–  2003. – Vol. 36. – N 11. – P. 1455–1463.

67

307.Olson J. L. Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model / J. L. Olson, R. J. Courtney, B. Rouhani et al. // Ocul. Immunol. Inflam. – 2009. – Vol. 17. – P. 195–200.

308.Onishi T. An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma /

T.Onishi, Y. Ohishi, K. Imagawa et al. // BJU Int. – 1999. – Vol. 83. –

P.488–492.

309.Osada T. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients / T. Osada, G. Chong, R. Tansik et al. // Cancer Immunol. Immunother. – 2008. – Vol. 57. – N 8. –

P.1115–1124.

310.O’Shea J. J. Jaks and Stats as therapeutic targets / J. J. O’Shea,

R.Visconti, T. P. Cheng, M. Gadina // Ann. Rheum. Dis. – 2000. – Vol. 59. – P. i115–i118.

311.Ostrand-Rosenberg S. Immune surveillance: a balance between proand anti-tumor immunity / S. Ostrand-Rosenberg // Curr. Opin. Genet. Dev. – 2008. – Vol. 18. – N 1. – P. 11–18.

312.Ouaked N. Regulation of the foxp3 gene by the Th1 cytokines: the role of IL-27–induced STAT1 / N. Ouaked, P. Y. Mantel, C. Bassin et al. // J. Immunol. – 2009. – Vol. 182. – N 2. – P. 1041–1049.

313.Overwijk W. W. Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications / W. W. Overwijk, K. S. Schluns // Clin. Immunol. – 2009. – Vol. 132. – N 2. – P. 153–165.

314.Page G. Plasma cell-like morphology of Th1–cytokine-producing cells associated with the loss of CD3 expression / G. Page, A. Sattler, S. Kersten et al. // Am. J. Pathol. – 2004. – Vol. 164. – N 2. –

P.409–417.

315.Palucka A. K. Dendritic cells: a critical player in cancer therapy? / A. K. Palucka, H. Ueno, J. Fay, J. Banchereau // J. Immunother. – 2008. – Vol. 31. – N 9. – P. 793–805.

316.Pan P. Y. Advancements in immune tolerance / P. Y. Pan, J. Ozao,

Z.Zhou, S. H. Chen // Adv. Drug Deliv. Rev. – 2008. – Vol. 60. – N 2. – P. 91–105.

317.Pan S. Etk / Bmx as a tumor necrosis factor receptor type 2–specific kinase: role in endothelial cell migration and angiogenesis / S. Pan,

P.An, R. Zhang et al. // Mol. Cell. Biol. – 2002. – Vol. 22. – N 21. –

P.7512–7523.

318.Park J. S. Interleukin-8 production in tuberculous pleurisy: role of mesothelial cells stimulated by cytokine network involving tumour necrosis factor-alpha and interleukin-1 beta / J. S. Park, Y. S. Kim, Y. K. Jee et al. // Scand. J. Immunol. – 2003. – Vol. 57. – N 5. – P. 463–469.

319.Park S. H. Shift toward T helper 1 cytokines by type II collagenreactive T cells in patients with rheumatoid arthritis // S. H. Park, D. J. Min, M. L. Cho et al. // Arthritis Rheum. – 2001. – Vol. 44. – N 3. – P. 561–569.

68

320.Park S. The dual effects of interleukin-18 in tumor progression /

S.Park, S. Cheon, D. Cho // Cell. Mol. Immunol. – 2007. – Vol. 4. – N 5. – P. 329–335.

321.Pasquinelli V. IFN-gamma production during active tuberculosis is regulated by mechanisms that involve IL-17, SLAM, and CREB / V. Pasquinelli, J. C. Townsend, J. O. Jurado et al. // J. Infect. Dis. – 2009. – Vol. 199. – N 5. – P. 661–665.

322.Peña L. L. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables / L. L. Peña, A. I. Nieto, D. Pérez-Alenza et al. // J. Vet. Diagn. Invest. – 1998. – Vol. 10. – N 3. – P. 237–246.

323.Petreaca M. L. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8 / CXCL8) is required for IL-8 / CXCL8–induced endothelial permeability / M. L. Petreaca, M. Yao,

Y.Lui et al. // Mol. Biol. Cell. – 2007. – Vol. 18. – P. 5014–5023.

324.PettitS. J.Immuneselectioninneoplasia:towardsamicroevolutionary model of cancer development / S. J. Pettit, K. Seymour, E. O’Flaherty, J. A. Kirby // Br. J. Cancer. – 2000. – Vol. 82. – N 12. – P. 1900–1906.

325.Phelan J. D. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies / J.D . Phelan, T. Orekov, F. D. Finkelman // J. Immunol.–  2008. – Vol. 180. – N 1. – P. 44–48.

326.Pollard J. W. Macrophages define the invasive microenvironment in breast cancer / J. W. Pollard // J. Leukoc. Biol. – 2008. – Vol. 84. – N 3. – P. 623–630.

327.Popivanova B. K. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis / B.K . Popivanova, K. Kitamura,

Y.Wu et al. // J. Clin. Invest.–  2008. – Vol. 118. – N 2. – P. 560–570.

328.Potter J. D. Colorectal cancer: molecules and populations / J. D. Potter // J. Natl. Cancer. Inst. – 1999. – Vol. 91. – N 11. – Р. 916–932.

329.Pradeep A. R. Exploring the role of Th1 cytokines: interleukin-17and in- terleukin-18 in periodontal health and disease // A.R . Pradeep, P. Hadge,

S.Chowdhry et al. // J. Oral. Sci.–  2009. – Vol. 51. – N 2. – P. 261–266.

330.Prokopchuk O. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions /

O.Prokopchuk, Y. Liu, D. Henne-Bruns, M. Kornmann // Br. J. Cancer. – 2005. – Vol. 92. – N 5. – P. 921–928.

331.Pugliese A. Central and peripheral autoantigen presentation in immune tolerance / A. Pugliese // Immunology. – 2004. – Vol. 111. – N 2. – P. 138–146.

332.Puren A. J. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1 beta via TNFalpha production from non-CD14+ human blood mononuclear cells / A. J. Puren, G. Fantuzzi, Y. Gu et al. // J. Clin. Invest. – 1998. – Vol. 101. – N 3. – P. 711–721.

333.Quante M. Inflammation and stem cells in gastrointestinal carcinogenesis / M. Quante, T. C. Wang // Physiology (Bethesda). – 2008. – Vol. 23. – P. 350–359.

69

334.Rajesh V. Lalla. Expression of Vascular Endothelial Growth Factor Receptors on tumor cells in head and neck squamous cell carcinoma / V. Lalla. Rajesh, BDS, PhD et al. // Arch. Otolaryngol. Head. Neck. Surg. – 2003. – Vol. 129. – Vol. 8. – P. 882–888.

335.Raman D. Role of chemokines in tumor growth / D. Raman, P.J . Baugher, Y. M. Thu, A. Richmond // Cancer Lett.–  2007. – Vol. 256. – N 2. – P. 137–165.

336.Revoltella R. P. Natural and therapeutically-induced antibodies to cytokines / R. P. Revoltella // Biotherapy. – 1998. – Vol. 10. – N 4. – P. 321–331.

337.Robb R. J. Heterogeneity of Human T-Cell Growth Factor (S) due to variable glycosylation / R. J. Robb, K. A. Smith // Mol. Immunol. – 1981. – Vol. 18. – P. 1087–1094.

338.Robertson M. J. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer / M. J. Robertson, J. W. Mier, T. Logan et al. // Clin. Cancer Res. – 2006. – Vol. 12. – N 14. – P. 4265–4273.

339.Roca H. CCL2 and interleukin-6 promote survival of human CD11 b+ peripheral blood mononuclear cells and induce M2–type macrophage polarization / H. Roca, Z. S. Varsos, S. Sud et al // J. Biol. Chem. – 2009. – Vol. 284. – P. 34342–34354.

340.Rose-John S. Interleukin-6 biology is coordinated by membranebound and soluble receptors: role in inflammation and cancer / S. Rose-John, J. Scheller, G. Elson, S. A. Jones // J. Leukoc. Biol. – 2006. – Vol. 80. – N 2. – P.227–236.

341.RossC.HighavidityIFN-neutralizingantibodiesinpharmaceutically prepared human IgG / C. Ross, M. Svenson, M. B. Hansen et al. // J. Clin. Invest. – 1995. – Vol. 95. – N 5. – P. 1974–1978.

342.Rubie C. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer / C. Rubie, V. O. Frick, S. Pfeil et al. // World J. Gastroenterol. – 2007. – Vol. 13. – N 37. – P. 4996–5002.

343.Ruddy M. J. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT / enhancerbinding protein family members / M. J. Ruddy, G. C. Wong, X. K. Liu et al. // J. Biol. Chem. – 2004. – Vol. 279. – N 4. – P. 2559–2567.

344.Saha B. Gene modulation and immunoregulatory roles of interferon gamma / B. Saha, S. Jyothi Prasanna, B. Chandrasekar, D. Nandi // Cytokine. – 2010. – Vol. 50. – N 1. – P. 1–14.

345.Sakai A. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren’s syndrome, and amplification of IL-17–medi- ated secretion of inflammatory cytokines from salivary gland cells by IL-18 / A. Sakai, Y. Sugawara, T. Kuroishi et al. // J. Immunol. – 2008. – Vol. 181. – N 4. – P. 2898–2906.

346.Scagnolari C. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed

70